These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29278535)

  • 21. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
    Gebru MT; Wang HG
    J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLT3 Inhibition in Acute Myeloid Leukemia.
    Smith CC
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance in mutant FLT3-positive AML.
    Weisberg E; Sattler M; Ray A; Griffin JD
    Oncogene; 2010 Sep; 29(37):5120-34. PubMed ID: 20622902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
    Prescott H; Kantarjian H; Cortes J; Ravandi F
    Expert Opin Emerg Drugs; 2011 Sep; 16(3):407-23. PubMed ID: 21417961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting FLT3 to treat leukemia.
    Konig H; Levis M
    Expert Opin Ther Targets; 2015 Jan; 19(1):37-54. PubMed ID: 25231999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
    Bohl SR; Bullinger L; Rücker FG
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RSK Inhibition Induces Apoptosis by Downregulating Protein Synthesis in a Variety of Acute Myeloid Leukemia Cell Lines.
    Katayama K; Nishihata A
    Biol Pharm Bull; 2021 Dec; 44(12):1843-1850. PubMed ID: 34602526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.
    Grunwald MR; Levis MJ
    Semin Hematol; 2015 Jul; 52(3):193-9. PubMed ID: 26111466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
    Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
    Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
    Grunwald MR; Levis MJ
    Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular pathogenesis of AML: translating insights to the clinic.
    Levine RL
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):245-8. PubMed ID: 24309525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?
    Pratz KW; Luger SM
    Curr Opin Hematol; 2014 Mar; 21(2):72-8. PubMed ID: 24468836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.